The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide (GIP) in man.
The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide were investigated in six healthy volunteers. At the maximum infusion dose (0 . 5 pmol kg-1 min-1) a plateau concentration of 115 +/- 5 . 0 pmol/l plasma was obtained. On discontinuation of the infusion, the half-time of disappearance was calculated to be 20 . 3 +/- 1 . 2 min. The metabolic clearance rate was 2 . 6 +/- 0 . 1 ml kg-1 min-1 and the apparent space of distribution was 75 . 8 +/- 5 . 7 ml kg-1. Blood glucose, pancreatic and gastrointestinal hormones remained at basal concentrations throughout. No side effects were noted by any of the subjects studied.
D000328:Adult; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000008:administration & dosage / Q000097:blood*; D005768:Gastrointestinal Hormones / Q000097:blood*; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D007328:Insulin / Q000097:blood; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D010187:Pancreatic Hormones / Q000097:blood; D013552:Swine
D001786:Blood Glucose; D005768:Gastrointestinal Hormones; D007328:Insulin; D010187:Pancreatic Hormones; D005749:Gastric Inhibitory Polypeptide